通过Snai1介导的血管功能障碍的正常化增加了癌症癌症的药物反应
Helene Hoffmann1,2, Martin Wartenberg3,4, Sandra Vorlova5
1Institute of Anatomy and Cell Biology, Universität Würzburg, Koellikerstrasse 6, 97070, Würzburg, Germany.
向Snai1转录因子可以改善瘤血管功能,增强化疗的治疗效果,减少副作用. 这种方法重新设计瘤血管系统,以便在不降低血管密度的情况下更好地治疗癌症.
科学领域:
- 在瘤学瘤学.
- 血管生物学 血管生物学
- 分子生物学分子生物学
背景情况:
- 瘤血管通常功能不良,阻碍药物输送和疗效.
- 抗血管生成疗法可能会恶化血管功能障碍和药物输送.
- 在不降低密度的情况下恢复血管功能是一个治疗挑战.
研究的目的:
- 研究涉及表皮-介质细胞过渡 (EMT) 的转录因子 (TF) 作为瘤血管功能障碍的调节者.
- 评估Snai1作为改善瘤血管功能的关键标.
主要方法:
- 对内皮细胞进行体外研究,以评估Snai1在透性和细胞迁移中的作用.
- 在体内实验中,使用内皮特异性异构糖Snai1敲除 (Snai1KD) 鼠标与植入瘤进行了实验.
- 评估瘤血管质量,氧化,转移以及药物输送/分发.
主要成果:
- 在体外,Snai1调节内皮透性,瘤细胞转移和尖端/茎细胞的形成.
- 特定于内皮细胞的Snai1 knockdown改善了血管质量,氧化,并减少了瘤转移.
- 在Snai1KD瘤中,化学疗法药物的分布得到了增强和更加均,改善了治疗反应.
结论:
- Snai1是瘤血管功能障碍的关键调节者.
- 在不影响血管密度的情况下恢复血管平衡在恶性瘤中是可以实现的.
- 针对Snai1提供了一种改善抗癌药物输送和减少毒性的策略.
更多相关视频
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
11:07In Vivo Imaging and Quantitation of the Host Angiogenic Response in Zebrafish Tumor Xenografts
Published on: August 14, 2019
相关概念视频
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
